Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years
with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The
primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate
delayed-release capsules will result in improvement in liver disease severity.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators:
National Cancer Institute (NCI) National Center for Advancing Translational Science (NCATS) Raptor Pharmaceuticals